Light Sciences Oncology
Founded Year
1994Stage
Unattributed VC | DeadTotal Raised
$175.76MLast Raised
$2.03MAbout Light Sciences Oncology
Light Sciences Oncology (LSO) is developing Talaporfin Sodium for solid tumors as well as other indications such as BPH. Talaporfin Sodium is a water-soluble drug targeted by a small, single-use, disposable drug activator included with the drug. Talaporfin Sodium is designed to provide tolerable, effective, and repeatable treatments for patients. LSO has completed treatment of patients in a Phase 3 trial of Talaporfin Soduim in hepatocellular carcinoma (HCC), a Phase 3 trial for metastatic colorectal cancer (MCRC) and in Phase 1 and Phase 2 clinical trials in benign prostatic hyperplasia (BPH), or enlargement of the prostate.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Light Sciences Oncology Patents
Light Sciences Oncology has filed 13 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
8/6/2007 | 8/13/2019 | Vascular diseases, Cardiology, Transcription factors, Implants (medicine), Interventional radiology | Grant |
Application Date | 8/6/2007 |
|---|---|
Grant Date | 8/13/2019 |
Title | |
Related Topics | Vascular diseases, Cardiology, Transcription factors, Implants (medicine), Interventional radiology |
Status | Grant |
Latest Light Sciences Oncology News
Aug 17, 2023
In a rare move, the FDA issued a notice of noncompliance to an oncology company for failing to submit clinical data on its treatment for benign prostatic hyperplasia to a federal database. Under the Food and Drug Administration Amendments Act of 2007, sponsors are required to submit certain results from clinical trials to ClinicalTrials.gov, generally no later than one year after completion of the trial. They can be granted an extension if they submit a request for a delay in posting the data, though the request must be submitted by a certain deadline. Unlock this article instantly by becoming a free subscriber. You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news. SIGN UP
Light Sciences Oncology Frequently Asked Questions (FAQ)
When was Light Sciences Oncology founded?
Light Sciences Oncology was founded in 1994.
Where is Light Sciences Oncology's headquarters?
Light Sciences Oncology's headquarters is located at 12600 SE 38th Street, Bellevue.
What is Light Sciences Oncology's latest funding round?
Light Sciences Oncology's latest funding round is Unattributed VC.
How much did Light Sciences Oncology raise?
Light Sciences Oncology raised a total of $175.76M.
Who are the investors of Light Sciences Oncology?
Investors of Light Sciences Oncology include New Science Ventures, Scandinavian Life Science Venture, CDIB Capital Group, Johnson & Johnson Innovation, Burrill & Company and 13 more.
Who are Light Sciences Oncology's competitors?
Competitors of Light Sciences Oncology include ALung Technologies, Mercator MedSystems, eNeura Therapeutics, DFine, Pathfinder Therapeutics and 10 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Light Sciences Oncology to Competitors
Novasys Medical, formerly Genesis Medical, is a medical device company that develops therapies in women's health. The company's initial focus is the development and commercialization of the Renessa System, a non-surgical approach to the treatment of female stress urinary incontinence (SUI). The company was founded in 1999 and is based in Newark, California.
eNeura Therapeutics develops the use of portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for the treatment of migraines.
NAS Medical develops, manufactures, and sells radiation therapy products for use in cancer treatment.
20/10 PERFECT VISION OPERATIONS GmbH of Heidelberg, Germany, develops, manufactures and markets technologies for raising refractive surgery well beyond current expectations. The company's expertise lies in diagnostic as well as therapeutic technologies. 20/10 PERFECT VISION's FEMTEC femtosecond laser workstation is set to revolutionize the ophthalmic surgery market, while keeping ease-of-use and patient safety as primary objectives.
Aethlon Medical is the developer of the Hemopurifier - medical device that aims to treat infectious disease.
HistoSonics develops a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquefy unwanted tissue and tumors at sub-cellular levels. The company is focused on the development of its Edison platform, combining imaging with sensing technology to deliver personalized external beam treatments with precision and control, reducing the side effects of conventional therapies. The company was founded in 2009 and is based in Minneapolis, Minnesota.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
